ResearcherKeio UniversityActive in the last 2 years
Yosuke Uematsu
Matched on ORCID iD 0009-0004-8694-6549; OpenAlex author ID A5014784355. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2025: 2 papers · 2026: 2 papers
Papers 4
- Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
- Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
- Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
- Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Co-author DOI 10.1245/s10434-025-17661-7↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Minoru Kitago · 4 shared papers, 2025–2026 · strength 0.86
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Yohei Masugi · 3 shared papers, 2025–2026 · strength 0.65
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Sho Uemura · 3 shared papers, 2025–2026 · strength 0.65
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Yuta Abe · 2 shared papers, 2025–2026 · strength 0.48
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Yutaka Nakano · 2 shared papers, 2025–2026 · strength 0.48
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Yuko Kitagawa · 2 shared papers, 2025–2026 · strength 0.48
- Paper Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. DOI 10.1007/s00535-026-02343-2↗
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Yosuke Inoue · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Kiyoshi Hasegawa · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Manabu Takamatsu · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Tsuyoshi Takeda · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Tatsunori Suzuki · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Tsuyoshi Hamada · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Yu Takahashi · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Yousuke Nakai · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Mitsuhiro Fujishiro · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Naoki Sasahira · 2 shared papers, 2025–2026 · strength 0.38
- Paper Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. DOI 10.1038/s41416-025-03308-7↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Shutaro Hori · 1 shared paper, 2026 · strength 0.26
- Gaku Shimane · 1 shared paper, 2026 · strength 0.26
- Koichi Aiura · 1 shared paper, 2025 · strength 0.22
- Sojun Hoshimoto · 1 shared paper, 2025 · strength 0.22
- Yutaka Endo · 1 shared paper, 2025 · strength 0.22
- Yutaka Takigawa · 1 shared paper, 2025 · strength 0.22
- Junichi Matsui · 1 shared paper, 2025 · strength 0.22
- Yusuke Kazami · 1 shared paper, 2026 · strength 0.21
- Satoru Abe · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.